{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "exchange": "NMS", "regularMarketChangePercent": 2.2222269, "regularMarketPrice": 0.92, "firstTradeDateMilliseconds": 1539955800000, "priceHint": 4, "earningsTimestamp": 1683808200, "earningsTimestampStart": 1691584200, "earningsTimestampEnd": 1692016200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.6, "epsForward": -0.23, "epsCurrentYear": -0.38, "priceEpsCurrentYear": -2.4210527, "sharesOutstanding": 99349800, "bookValue": 0.515, "fiftyDayAverage": 1.0328, "fiftyDayAverageChange": -0.11279994, "fiftyDayAverageChangePercent": -0.10921761, "twoHundredDayAverage": 1.50795, "twoHundredDayAverageChange": -0.58794993, "twoHundredDayAverageChangePercent": -0.38990018, "marketCap": 91401816, "forwardPE": -4.0, "priceToBook": 1.7864078, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "shortName": "RVL Pharmaceuticals plc", "longName": "RVL Pharmaceuticals plc", "messageBoardId": "finmb_579085729", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 0.02000004, "regularMarketTime": 1684180778, "regularMarketDayHigh": 0.94, "regularMarketDayRange": "0.9 - 0.94", "regularMarketDayLow": 0.9, "regularMarketVolume": 35275, "regularMarketPreviousClose": 0.9, "bid": 0.0, "ask": 0.0, "bidSize": 11, "askSize": 22, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 0.9, "averageDailyVolume3Month": 71701, "averageDailyVolume10Day": 78930, "fiftyTwoWeekLowChange": 0.19999999, "fiftyTwoWeekLowChangePercent": 0.27777776, "fiftyTwoWeekRange": "0.72 - 2.99", "fiftyTwoWeekHighChange": -2.07, "fiftyTwoWeekHighChangePercent": -0.69230765, "fiftyTwoWeekLow": 0.72, "fiftyTwoWeekHigh": 2.99, "displayName": "RVL Pharmaceuticals", "symbol": "RVLP"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "400 Crossing Boulevard", "city": "Bridgewater", "state": "NJ", "zip": "08807", "country": "United States", "phone": "908 809 1300", "fax": "908 809 1301", "website": "https://www.rvlpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.", "fullTimeEmployees": 125, "companyOfficers": [{"maxAge": 1, "name": "Mr. Brian A. Markison", "age": 63, "title": "Chairman, Pres, CEO & Principal Financial Officer", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 525000, "fmt": "525k", "longFmt": "525,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James D. Schaub", "age": 40, "title": "Exec. VP & COO", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": {"raw": 367200, "fmt": "367.2k", "longFmt": "367,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher A. Klein", "age": 57, "title": "Gen. Counsel & Sec.", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 367200, "fmt": "367.2k", "longFmt": "367,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael J. DePetris", "age": 45, "title": "Principal Accounting Officer", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jarret  Miller", "title": "Exec. VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}